Abstract
We appreciate the letter from Marquez et al .1 regarding our article concerning the interest of hydroquinidine (HQ) in preventing ventricular arrhythmias in asymptomatic Brugada syndrome patients.2 In keeping with the first study published by our institution,3 the lower dose of HQ intake by patients was 600 mg/day in case of good tolerance. Hydroquinidine was increased to 900 mg/day if ventricular fibrillation (VF) was still inducible with a plasma level under the therapeutic range. …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
